MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Anavex Life Sciences Corp

Geschlossen

BrancheGesundheitswesen

10.98 -0.72

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.72

Max

11.2

Schlüsselkennzahlen

By Trading Economics

Einkommen

915K

-11M

Angestellte

42

EBITDA

106K

-12M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+157.69% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

201M

928M

Vorheriger Eröffnungskurs

11.7

Vorheriger Schlusskurs

10.98

Nachrichtenstimmung

By Acuity

50%

50%

154 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Anavex Life Sciences Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Juli 2025, 21:01 UTC

Ergebnisse

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

18. Juli 2025, 20:46 UTC

Ergebnisse

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18. Juli 2025, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. Juli 2025, 20:36 UTC

Ergebnisse

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18. Juli 2025, 20:16 UTC

Akquisitionen, Fusionen, Übernahmen

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18. Juli 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Juli 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18. Juli 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18. Juli 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18. Juli 2025, 18:24 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18. Juli 2025, 18:19 UTC

Ergebnisse

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18. Juli 2025, 18:11 UTC

Akquisitionen, Fusionen, Übernahmen

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18. Juli 2025, 18:11 UTC

Ergebnisse

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18. Juli 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18. Juli 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18. Juli 2025, 16:28 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. Juli 2025, 16:22 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Energy & Utilities Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

18. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Juli 2025, 16:04 UTC

Ergebnisse

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18. Juli 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18. Juli 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18. Juli 2025, 15:47 UTC

Market Talk
Ergebnisse

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Peer-Vergleich

Kursveränderung

Anavex Life Sciences Corp Prognose

Kursziel

By TipRanks

157.69% Vorteil

12-Monats-Prognose

Durchschnitt 28.5 USD  157.69%

Hoch 42 USD

Tief 15 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Anavex Life Sciences Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

8.275 / 9.312Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

154 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.